Cargando…
The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing
BACKGROUND: iPrevent estimates breast cancer (BC) risk and provides tailored risk management information. OBJECTIVE: The objective of this study was to assess the usability and acceptability of the iPrevent prototype. METHODS: Clinicians were eligible for participation in the study if they worked in...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334700/ https://www.ncbi.nlm.nih.gov/pubmed/30684421 http://dx.doi.org/10.2196/formative.9935 |
_version_ | 1783387770499104768 |
---|---|
author | Lo, Louisa L Collins, Ian M Bressel, Mathias Butow, Phyllis Emery, Jon Keogh, Louise Weideman, Prue Steel, Emma Hopper, John L Trainer, Alison H Mann, Gregory B Bickerstaffe, Adrian Antoniou, Antonis C Cuzick, Jack Phillips, Kelly-Anne |
author_facet | Lo, Louisa L Collins, Ian M Bressel, Mathias Butow, Phyllis Emery, Jon Keogh, Louise Weideman, Prue Steel, Emma Hopper, John L Trainer, Alison H Mann, Gregory B Bickerstaffe, Adrian Antoniou, Antonis C Cuzick, Jack Phillips, Kelly-Anne |
author_sort | Lo, Louisa L |
collection | PubMed |
description | BACKGROUND: iPrevent estimates breast cancer (BC) risk and provides tailored risk management information. OBJECTIVE: The objective of this study was to assess the usability and acceptability of the iPrevent prototype. METHODS: Clinicians were eligible for participation in the study if they worked in primary care, breast surgery, or genetics clinics. Female patients aged 18-70 years with no personal cancer history were eligible. Clinicians were first familiarized with iPrevent using hypothetical paper-based cases and then actor scenarios; subsequently, they used iPrevent with their patients. Clinicians and patients completed the System Usability Scale (SUS) and an Acceptability questionnaire 2 weeks after using iPrevent; patients also completed measures of BC worry, anxiety, risk perception, and knowledge pre- and 2 weeks post-iPrevent. Data were summarized using descriptive statistics. RESULTS: The SUS and Acceptability questionnaires were completed by 19 of 20 clinicians and 37 of 43 patients. Usability was above average (SUS score >68) for 68% (13/19) clinicians and 76% (28/37) patients. The amount of information provided by iPrevent was reported as “about right” by 89% (17/19) clinicians and 89% (33/37) patients and 95% (18/19) and 97% (36/37), respectively, would recommend iPrevent to others, although 53% (10/19) clinicians and 27% (10/37) patients found it too long. Exploratory analyses suggested that iPrevent could improve risk perception, decrease frequency of BC worry, and enhance BC prevention knowledge without changing state anxiety. CONCLUSIONS: The iPrevent prototype demonstrated good usability and acceptability. Because concerns about length could be an implementation barrier, data entry has been abbreviated in the publicly available version of iPrevent. |
format | Online Article Text |
id | pubmed-6334700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | JMIR Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-63347002019-01-23 The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing Lo, Louisa L Collins, Ian M Bressel, Mathias Butow, Phyllis Emery, Jon Keogh, Louise Weideman, Prue Steel, Emma Hopper, John L Trainer, Alison H Mann, Gregory B Bickerstaffe, Adrian Antoniou, Antonis C Cuzick, Jack Phillips, Kelly-Anne JMIR Form Res Original Paper BACKGROUND: iPrevent estimates breast cancer (BC) risk and provides tailored risk management information. OBJECTIVE: The objective of this study was to assess the usability and acceptability of the iPrevent prototype. METHODS: Clinicians were eligible for participation in the study if they worked in primary care, breast surgery, or genetics clinics. Female patients aged 18-70 years with no personal cancer history were eligible. Clinicians were first familiarized with iPrevent using hypothetical paper-based cases and then actor scenarios; subsequently, they used iPrevent with their patients. Clinicians and patients completed the System Usability Scale (SUS) and an Acceptability questionnaire 2 weeks after using iPrevent; patients also completed measures of BC worry, anxiety, risk perception, and knowledge pre- and 2 weeks post-iPrevent. Data were summarized using descriptive statistics. RESULTS: The SUS and Acceptability questionnaires were completed by 19 of 20 clinicians and 37 of 43 patients. Usability was above average (SUS score >68) for 68% (13/19) clinicians and 76% (28/37) patients. The amount of information provided by iPrevent was reported as “about right” by 89% (17/19) clinicians and 89% (33/37) patients and 95% (18/19) and 97% (36/37), respectively, would recommend iPrevent to others, although 53% (10/19) clinicians and 27% (10/37) patients found it too long. Exploratory analyses suggested that iPrevent could improve risk perception, decrease frequency of BC worry, and enhance BC prevention knowledge without changing state anxiety. CONCLUSIONS: The iPrevent prototype demonstrated good usability and acceptability. Because concerns about length could be an implementation barrier, data entry has been abbreviated in the publicly available version of iPrevent. JMIR Publications 2018-11-07 /pmc/articles/PMC6334700/ /pubmed/30684421 http://dx.doi.org/10.2196/formative.9935 Text en ©Louisa L Lo, Ian M Collins, Mathias Bressel, Phyllis Butow, Jon Emery, Louise Keogh, Prue Weideman, Emma Steel, John L Hopper, Alison H Trainer, Gregory B Mann, Adrian Bickerstaffe, Antonis C Antoniou, Jack Cuzick, Kelly-Anne Phillips. Originally published in JMIR Formative Research (http://formative.jmir.org), 07.11.2018. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Formative Research, is properly cited. The complete bibliographic information, a link to the original publication on http://formative.jmir.org, as well as this copyright and license information must be included. |
spellingShingle | Original Paper Lo, Louisa L Collins, Ian M Bressel, Mathias Butow, Phyllis Emery, Jon Keogh, Louise Weideman, Prue Steel, Emma Hopper, John L Trainer, Alison H Mann, Gregory B Bickerstaffe, Adrian Antoniou, Antonis C Cuzick, Jack Phillips, Kelly-Anne The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing |
title | The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing |
title_full | The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing |
title_fullStr | The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing |
title_full_unstemmed | The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing |
title_short | The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing |
title_sort | iprevent online breast cancer risk assessment and risk management tool: usability and acceptability testing |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334700/ https://www.ncbi.nlm.nih.gov/pubmed/30684421 http://dx.doi.org/10.2196/formative.9935 |
work_keys_str_mv | AT lolouisal theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT collinsianm theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT bresselmathias theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT butowphyllis theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT emeryjon theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT keoghlouise theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT weidemanprue theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT steelemma theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT hopperjohnl theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT traineralisonh theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT manngregoryb theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT bickerstaffeadrian theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT antoniouantonisc theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT cuzickjack theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT phillipskellyanne theipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT lolouisal ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT collinsianm ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT bresselmathias ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT butowphyllis ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT emeryjon ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT keoghlouise ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT weidemanprue ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT steelemma ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT hopperjohnl ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT traineralisonh ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT manngregoryb ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT bickerstaffeadrian ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT antoniouantonisc ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT cuzickjack ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting AT phillipskellyanne ipreventonlinebreastcancerriskassessmentandriskmanagementtoolusabilityandacceptabilitytesting |